ValiSeek – ValiRx unveils positive results from VAL401 Phase II lung cancer trial

Below, we are re-publishing the news issued by ValiSeek on the 12th of December 2017

ValiSeek – Clinical Development Update on VAL401

Dr Suzy Dilly, CEO of ValiSeek provides a positive update on the clinical progress of VAL401, the anti-cancer compound. The Company has released positive formal data pertaining to disease impact. The results demonstrate that the VAL401 treatment has a statistically significant improvement in Overall Survival for patients with non-small cell lung cancer compared to those receiving no treatment.

Further information is available at: 

* The study is conducted by Clinical Accelerator

This entry was posted in Clinical Accelerator. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s